Literature DB >> 21811910

Antiretroviral therapy 2010 update: current practices and controversies.

Matthew Grant1, Rafik Samuel, Robert L Bettiker, Byungse Suh.   

Abstract

Over the past four years, significant advances have been made in human immunodeficiency virus (HIV) therapy. In addition to the release of two new classes of antiretrovirals, our understanding of the older antiretrovirals continues to improve. Multiple combination pills have been brought to market, simplifying the regimens for patient ease. New controversies have arisen, notably the role of antiretrovirals in the chronic inflammatory state that HIV infection produces, which may lead to excess cardiac, renal, and hepatic mortality. The optimum time to initiate antiretroviral therapy remains unknown but clinicians are treating HIV infection earlier in its course. In this article, we review these and other new issues relating to the care of the HIV patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21811910     DOI: 10.1007/s12272-011-0701-3

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  2 in total

1.  The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood.

Authors:  Mark A Marzinke; Autumn Breaud; Teresa L Parsons; Myron S Cohen; Estelle Piwowar-Manning; Susan H Eshleman; William Clarke
Journal:  Clin Chim Acta       Date:  2014-03-22       Impact factor: 3.786

2.  HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.

Authors:  Tianshu Xiao; Gary Frey; Qingshan Fu; Christy L Lavine; David A Scott; Michael S Seaman; James J Chou; Bing Chen
Journal:  Nat Chem Biol       Date:  2020-03-09       Impact factor: 15.040

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.